/CAPR
CAPR Stock - Capricor Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$27.81+6.19%
+$1.62 (+6.19%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.97
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+64.4%upside
Target: $45.72
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CAPR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$27.53 – $28.09
TARGET (TP)$45.71
STOP LOSS$25.59
RISK/REWARD1:8.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.61
52W High$40.37
52W Low$4.30
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $22.27M | $25.18M | $2.55M | $244,898 | $310,250 |
| Gross Profit | $-27,698,120 | $-11,269,973 | $-19,265,480 | $244,898 | $310,250 |
| Gross Margin | -124.4% | -44.8% | -755.1% | 100.0% | 100.0% |
| Operating Income | $-42,564,842 | $-24,077,859 | $-29,697,383 | $-20,938,442 | $-13,689,971 |
| Net Income | $-40,467,186 | $-22,287,542 | $-29,019,532 | $-20,022,520 | $-13,657,028 |
| Net Margin | -181.7% | -88.5% | -1137.4% | -8175.9% | -4401.9% |
| EPS | $-1.15 | $-0.83 | $-1.18 | $-0.87 | $-0.88 |
Company Overview
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish0 Neutral/Bearish
Price Targets
$21
Average Target
↓ 26.0% Downside
Now
$8
Low
$21
Average
$35
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 30th 2025 | Alliance Global Partners | Initiation | Buy | $20 |
| June 26th 2025 | B. Riley Securities | Initiation | Buy | $21 |
| May 20th 2025 | Roth Capital | Initiation | Buy | $31 |
| October 21st 2024 | Piper Sandler | Initiation | Overweight | $35 |
| May 17th 2024 | Oppenheimer | Initiation | Outperform | $14 |
| January 5th 2024 | Cantor Fitzgerald | Initiation | Overweight | $8 |
| October 26th 2022 | Ladenburg Thalmann | Initiation | Buy | $15 |
Earnings History & Surprises
CAPRBeat Rate
50%
Last 16 quarters
Avg Surprise
-19.2%
EPS vs Estimate
Beats / Misses
8/7
1 met exactly
Latest EPS
$-0.54
Q4 2025
EPS Surprise History
Q4 23
+7.4%
$-0.25vs$-0.27
Q1 24
+91.3%
$-0.02vs$-0.23
Q2 24
-181.8%
$-0.31vs$-0.11
Q3 24
-9.4%
$-0.35vs$-0.32
Q4 24
-11.8%
$-0.38vs$-0.34
Q1 25
+48.4%
$-0.16vs$-0.31
Q2 25
-60.6%
$-0.53vs$-0.33
Q4 25
0.0%
$-0.54vs$-0.54
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 18, 2026 | $-0.51 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.54 | $-0.54 | 0.0% | = MET |
Q2 2025 | May 13, 2025 | $-0.33 | $-0.53 | -60.6% | ✗ MISS |
Q1 2025 | Mar 19, 2025 | $-0.31 | $-0.16 | +48.4% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.34 | $-0.38 | -11.8% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.32 | $-0.35 | -9.4% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.11 | $-0.31 | -181.8% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.23 | $-0.02 | +91.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q3 2023 | Aug 7, 2023 | $-0.34 | $-0.29 | +14.7% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.32 | $-0.31 | +3.1% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $0.33 | $-0.31 | -193.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.25 | $-0.29 | -16.0% | ✗ MISS |
Q2 2022 | May 10, 2022 | — | $-0.32 | — | — |
Q1 2022 | Mar 10, 2022 | $-0.19 | $-0.26 | -36.8% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.22 | $-0.17 | +22.7% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q2 2021 | May 13, 2021 | — | $-0.23 | — | — |
Latest News
Capricor Therapeutics And Parent Project Muscular Dystrophy to Host A Community Webinar To Share And Discuss Topline Results From Capricor's Phase 3 HOPE-3 Trial Evaluating Deramiocel
➖ NeutralBenzinga•Dec 16, 2025, 09:07 PM
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
📈 PositiveBenzinga•Dec 16, 2025, 04:34 PM•Also: , ,
B. Riley Securities Reiterates Buy on Capricor Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Dec 15, 2025, 04:48 PM
Piper Sandler Reiterates Overweight on Capricor Therapeutics, Raises Price Target to $45
📈 PositiveBenzinga•Dec 10, 2025, 05:25 PM
Capricor Therapeutics shares are trading higher after Oppenheimer raised the price target from $22 to $54.
📈 PositiveBenzinga•Dec 8, 2025, 04:40 PM
Oppenheimer Maintains Outperform on Capricor Therapeutics, Raises Price Target to $54
📈 PositiveBenzinga•Dec 8, 2025, 01:52 PM
Capricor Therapeutics Raises $150M in New Stock Offering Of 6M Shares Priced at $25 a Share
➖ NeutralBenzinga•Dec 5, 2025, 11:18 AM
Capricor Therapeutics Announces Proposed Public Offering Of Common Stock; Terms Not Disclosed
➖ NeutralBenzinga•Dec 4, 2025, 09:02 PM
Maxim Group Maintains Buy on Capricor Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Dec 4, 2025, 07:52 PM
HC Wainwright & Co. Maintains Buy on Capricor Therapeutics, Raises Price Target to $60
📈 PositiveBenzinga•Dec 3, 2025, 07:05 PM
Capricor Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 440.88%
📈 PositiveBenzinga•Dec 3, 2025, 02:46 PM
Capricor Therapeutics Shares Resume Trading
➖ NeutralBenzinga•Dec 3, 2025, 02:42 PM
Capricor Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 534.75%
📈 PositiveBenzinga•Dec 3, 2025, 02:37 PM
Capricor Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 452.20%
📈 PositiveBenzinga•Dec 3, 2025, 02:31 PM
Capricor Therapeutics Shares Resume Trade
➖ NeutralBenzinga•Dec 3, 2025, 02:30 PM
Capricor Therapeutics Exec Believes It Is "Prepared To Launch" Deramiocel; Says Co Passed Pre Licensing Inspection For San Diego Manufacturing Facility; Says Deramiocel Can Be Used With Any Therapeutics Currently Approved, Available Or Under Clinical Development
📈 PositiveBenzinga•Dec 3, 2025, 01:39 PM
Capricor Therapeutics shares are trading higher. The company announced topline results from its Phase 3 HOPE-3 Trial evaluating deramiocel cell therapy for Duchenne Muscular Dystrophy met its primary endpoint and secondary cardiac endpoint.
📈 PositiveBenzinga•Dec 3, 2025, 01:03 PM
Capricor Therapeutics shares are trading higher after the company announced topline results from its Phase 3 HOPE-3 Trial evaluating deramiocel cell therapy for Duchenne Muscular Dystrophy met its primary endpoint and secondary cardiac endpoint.
📈 PositiveBenzinga•Dec 3, 2025, 01:03 PM
Trading Halt: Halt status updated at 7:45:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 3, 2025, 12:45 PM
Capricor Therapeutics Shared Topline Results From Its Phase 3 HOPE-3 Trial Evaluating Deramiocel Cell Therapy For Duchenne Muscular Dystrophy, The Trial Met The Primary Endpoint And The Key Secondary Cardiac Endpoint
📈 PositiveBenzinga•Dec 3, 2025, 12:22 PM
Frequently Asked Questions about CAPR
What is CAPR's current stock price?
Capricor Therapeutics, Inc. (CAPR) is currently trading at $27.81 per share. The stock has moved +6.19% today.
What is the analyst price target for CAPR?
The average analyst price target for CAPR is $45.71, based on 1 analyst.
What sector is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CAPR's market cap?
Capricor Therapeutics, Inc. has a market capitalization of $1.27 billion, making it a small-cap company.
Does CAPR pay dividends?
No, Capricor Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACHV
Achieve Life Sciences, Inc.
$4.32
Mkt Cap: $0.2B
ALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
ARCT
Arcturus Therapeutics Holdings Inc.
$6.53
Mkt Cap: $0.2B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
IMMP
Immutep Limited
$2.63
Mkt Cap: $0.4B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
PRQR
ProQR Therapeutics N.V.
$2.21
Mkt Cap: $0.2B
TRDA
Entrada Therapeutics, Inc.
$10.98
Mkt Cap: $0.4B
VNDA
Vanda Pharmaceuticals Inc.
$6.75
Mkt Cap: $0.4B
Explore stocks similar to CAPR for comparison